Racura Advances RC220 Trial with First Hong Kong Patient Dosed
Racura Oncology Limited (ASX: RAC) has reached a key milestone in its Phase 1 CPACS clinical trial after administering RC220 to a third patient, marking the first treatment at its Hong Kong site. The dosing was completed without safety concerns, with no adverse events or dose-limiting toxicities observed at the administered level.
This latest treatment finalises enrolment for the initial dose cohort, allowing the study to progress to the next stage, subject to safety review. The upcoming phase will evaluate a higher dosage level under an updated trial protocol across multiple regions, including Australia, Hong Kong, and South Korea.
The study is designed to assess the safety profile, tolerability, and pharmacokinetics of RC220 in combination with chemotherapy, while also examining its potential cardioprotective and anticancer effects. The milestone supports continued advancement of the trial, with further patient recruitment and data generation expected in the next phase.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Racura Advances RC220 Trial with First Hong Kong Patient Dosed
Racura Oncology Limited (ASX: RAC) has reached a key milestone in its Phase 1 CPACS clinical trial after administering RC220 to a third patient, marking the first treatment at its Hong Kong site. The dosing was completed without safety concerns, with no adverse events or dose-limiting toxicities observed at the administered level.
This latest treatment finalises enrolment for the initial dose cohort, allowing the study to progress to the next stage, subject to safety review. The upcoming phase will evaluate a higher dosage level under an updated trial protocol across multiple regions, including Australia, Hong Kong, and South Korea.
The study is designed to assess the safety profile, tolerability, and pharmacokinetics of RC220 in combination with chemotherapy, while also examining its potential cardioprotective and anticancer effects. The milestone supports continued advancement of the trial, with further patient recruitment and data generation expected in the next phase.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au